GetTopicDetailResponse(id=41d4123661de, topicName=EGFR突變NSCLC, introduction=, content=埃萬妥單抗 拉澤替尼 EGFR突變NSCLC, image=null, comments=0, allHits=323, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Fri Jan 24 10:35:56 CST 2025, time=2025-01-24, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=500873, tagList=[TagDto(tagId=500873, tagName=EGFR突變NSCLC)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2249443, encodeId=73fa224944329, content=<a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃萬妥單抗#</a> <a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉澤替尼#</a> <a href='/topic/show?id=41d4123661de' target=_blank style='color:#2F92EE;'>#EGFR突變NSCLC#</a>, objectTitle=J Thorac Oncol | 埃萬妥單抗聯(lián)合拉澤替尼在 EGFR 突變 NSCLC 患者中展現(xiàn)出顯著抗腫瘤活性, objectType=article, longId=860876, objectId=c4758608e600, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250124/1737648845389_6145188.png, objectUrl=/article/show_article.do?id=c4758608e600, replyNumber=0, likeNumber=40, createdTime=2025-01-24, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=c4758608e600, moduleTitle=J Thorac Oncol | 埃萬妥單抗聯(lián)合拉澤替尼在 EGFR 突變 NSCLC 患者中展現(xiàn)出顯著抗腫瘤活性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c4758608e600)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-01-24發(fā)表于陜西省
